688505 Stock Overview
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.70 |
| 52 Week High | HK$10.71 |
| 52 Week Low | HK$6.24 |
| Beta | 0.31 |
| 1 Month Change | 4.05% |
| 3 Month Change | -0.90% |
| 1 Year Change | -24.66% |
| 3 Year Change | -58.78% |
| 5 Year Change | n/a |
| Change since IPO | -54.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688505 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 8.5% | 4.5% | 2.2% |
| 1Y | -24.7% | -13.4% | -14.2% |
Return vs Industry: 688505 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 688505 underperformed the CN Market which returned -14.2% over the past year.
Price Volatility
| 688505 volatility | |
|---|---|
| 688505 Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 688505 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688505's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 948 | Da Jun Zhao | www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary
| 688505 fundamental statistics | |
|---|---|
| Market cap | CN¥6.13b |
| Earnings (TTM) | CN¥108.63m |
| Revenue (TTM) | CN¥850.73m |
19.2x
P/E Ratio2.5x
P/S RatioIs 688505 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688505 income statement (TTM) | |
|---|---|
| Revenue | CN¥850.73m |
| Cost of Revenue | CN¥74.08m |
| Gross Profit | CN¥776.66m |
| Other Expenses | CN¥668.03m |
| Earnings | CN¥108.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 15, 2024
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 91.29% |
| Net Profit Margin | 12.77% |
| Debt/Equity Ratio | 0% |
How did 688505 perform over the long term?
See historical performance and comparison